PL2993186T3 - Przeciwciało monoklonalne i sposób jego otrzymywania - Google Patents

Przeciwciało monoklonalne i sposób jego otrzymywania

Info

Publication number
PL2993186T3
PL2993186T3 PL15171431T PL15171431T PL2993186T3 PL 2993186 T3 PL2993186 T3 PL 2993186T3 PL 15171431 T PL15171431 T PL 15171431T PL 15171431 T PL15171431 T PL 15171431T PL 2993186 T3 PL2993186 T3 PL 2993186T3
Authority
PL
Poland
Prior art keywords
monoclonal antibody
monoclonal
antibody
Prior art date
Application number
PL15171431T
Other languages
English (en)
Inventor
Ramakrishnan Melarkode
Pradip Nair
Sundaraj David Rajkumar
Kedarnath Nanjund Sastry
Monalisa Chatterji
Laxmi Adhikary
Hema Balasubramanian
Jose Enrique Montero Casimiro
Josefa Lombardero Valladares
Rolando Perez Rodriguez
Original Assignee
Biocon Limited
Centro De Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41064805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2993186(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocon Limited, Centro De Inmunologia Molecular filed Critical Biocon Limited
Publication of PL2993186T3 publication Critical patent/PL2993186T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL15171431T 2008-03-14 2008-09-04 Przeciwciało monoklonalne i sposób jego otrzymywania PL2993186T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN650CH2008 2008-03-14
PCT/IN2008/000562 WO2009113083A1 (en) 2008-03-14 2008-09-04 A monoclonal antibody and a method thereof
EP08873217A EP2265644A4 (en) 2008-03-14 2008-09-04 MONOCLONAL ANTIBODY AND CORRESPONDING METHOD
EP15171431.8A EP2993186B1 (en) 2008-03-14 2008-09-04 A monoclonal antibody and a method thereof

Publications (1)

Publication Number Publication Date
PL2993186T3 true PL2993186T3 (pl) 2020-02-28

Family

ID=41064805

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15171431T PL2993186T3 (pl) 2008-03-14 2008-09-04 Przeciwciało monoklonalne i sposób jego otrzymywania

Country Status (26)

Country Link
US (7) US8524233B2 (pl)
EP (2) EP2265644A4 (pl)
JP (3) JP2011513479A (pl)
KR (1) KR20100126811A (pl)
CN (1) CN101970493A (pl)
AR (1) AR072247A1 (pl)
AU (1) AU2008352540B2 (pl)
BR (1) BRPI0822447A2 (pl)
CA (1) CA2716919C (pl)
CL (1) CL2009000618A1 (pl)
CO (1) CO6331445A2 (pl)
DK (1) DK2993186T3 (pl)
EA (1) EA201001467A1 (pl)
ES (1) ES2759075T3 (pl)
HK (1) HK1223941A1 (pl)
IL (1) IL207917A0 (pl)
MX (1) MX2010010085A (pl)
MY (1) MY159517A (pl)
NZ (1) NZ587632A (pl)
PL (1) PL2993186T3 (pl)
PT (1) PT2993186T (pl)
TW (1) TWI485160B (pl)
UA (1) UA104587C2 (pl)
UY (1) UY31710A (pl)
WO (1) WO2009113083A1 (pl)
ZA (1) ZA201005843B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101482959B1 (ko) * 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
EP2265644A4 (en) 2008-03-14 2011-04-27 Biocon Ltd MONOCLONAL ANTIBODY AND CORRESPONDING METHOD
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG11201401196WA (en) 2011-10-03 2014-05-29 Moderna Therapeutics Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
HUE059110T2 (hu) 2011-12-16 2022-10-28 Modernatx Inc Módosított MRNS készítmények
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF PROTEINS
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CU24312B1 (es) * 2013-07-23 2018-02-08 Biocon Ltd Métodos para controlar los niveles de fucosilación en proteínas
JP6530391B2 (ja) * 2013-07-23 2019-06-12 バイオコン・リミテッド Ｃｄ６結合パートナーの使用およびそれに基づく方法
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
CN104497141B (zh) * 2014-12-31 2017-10-10 百泰生物药业有限公司 抗人cd6分子的治疗性抗体
JP6930916B2 (ja) * 2015-02-12 2021-09-01 ユニヴァーシティ オブ サザン カリフォルニアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈｅｒｎ Ｃａｌｉｆｏｒｎｉａ 疾患予防および治療における成長ホルモン受容体の遮断剤
CN109311992B (zh) 2016-06-15 2022-10-18 克利夫兰临床基金会 用于治疗t细胞介导疾病的新型抗cd6抗体
WO2018073721A1 (en) * 2016-10-18 2018-04-26 Biocon Limited Use of itolizumab to reduce phosphorylation of cd6
DK3529274T3 (da) 2016-10-21 2024-06-17 Biocon Ltd Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus
CN108178797B (zh) * 2017-12-29 2020-12-01 西南大学 一种抗家蚕BmSRC多克隆抗血清、制备方法及应用
AU2019228508A1 (en) 2018-02-27 2020-09-17 Equillium, Inc. Anti CD6 antibodies for treating severe asthma
US20210395329A1 (en) * 2018-06-29 2021-12-23 City Of Hope Cd6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
SG11202109118XA (en) * 2019-02-26 2021-09-29 Equillium Inc Anti-cd6 antibody compositions and methods for treating lupus
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for preventing type 1 diabetes
KR20240055093A (ko) 2021-09-08 2024-04-26 센트로 데 인뮤놀러지아 모레큘러 과다 염증 반응으로 인한 세포 및 장기 손상 예방을 위한 항-cd6 단일클론항체의 용도

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US699755A (en) 1902-03-06 1902-05-13 Ira G Hoag Train-order box in connection with semaphores.
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
WO1995012614A1 (en) 1993-11-02 1995-05-11 Duke University Cd6 ligand
US5998172A (en) 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
SI1516628T1 (sl) 1995-07-27 2013-10-30 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
CA2249471A1 (fr) 1996-03-20 1997-09-25 Hoechst Marion Roussel Composes tricycliques ayant une activite vis-a-vis des integrines notamment vis-a-vis de l'integrine alphavbeta3, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
JP2001523956A (ja) * 1997-03-03 2001-11-27 ブリストル−マイヤーズ・スクイブ・カンパニー ヒトｃｄ６に対するモノクローナル抗体
AU7467898A (en) * 1997-04-21 1998-11-13 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
AU3633000A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
CA2904259C (en) 1999-05-07 2016-11-15 Genentech, Inc. Use of rituximab to treat vasculitis
AU5081401A (en) * 2000-03-16 2001-10-03 Genentech Inc Anti-tissue factor antibodies with enhanced anticoagulant potency
WO2001091793A1 (en) * 2000-05-26 2001-12-06 Smithkline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
ES2192128B1 (es) 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
EP1409018B1 (en) 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
US20040091490A1 (en) 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
CA2519408C (en) 2003-04-04 2011-01-18 Genentech, Inc. High concentration antibody and protein formulations
WO2005080432A2 (en) * 2004-02-19 2005-09-01 Genentech, Inc. Cdr-repaired antibodies
EP1753783B1 (en) 2004-06-03 2014-08-06 Novimmune SA Anti-cd3 antibodies and methods of use thereof
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
CA2595380A1 (en) 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
JP5905184B2 (ja) 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
WO2007147001A2 (en) 2006-06-14 2007-12-21 Imclone Systems Incorporated Lyophilized formulations of anti-egfr antibodies
BRPI0721097A2 (pt) 2006-12-11 2014-07-01 Hoffmann La Roche Formulação parenteral de anticorpo abeta
CN101199483B (zh) 2006-12-14 2011-01-26 上海中信国健药业股份有限公司 一种稳定的抗her2人源化抗体制剂
EP2119452B1 (en) 2006-12-26 2020-03-04 Centro de Inmunologia Molecular Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
KR101482959B1 (ko) 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
BRPI0806313A2 (pt) 2007-01-09 2011-09-06 Wyeth Corp Formulação de anticorpo anti-il-13; formulação em aerossol de um anticorpo anti-il-13; formulaçãoliofilizada de um anticorpo anti-il-13; composição farmacêutica para o tratamento de um transtorno relacionado a il-13; fabricação de uma composição farmacêutica ; método de tratamento de um transtorno relacionado a il-13; seringa injetável; dispositivo para administração nasal; emplastro transdérmico; bolsa intravenosa; kit compreendendo pelo menos um recipiente; kit; e seringa injetável previamente enchida
US8119133B2 (en) 2007-02-28 2012-02-21 Schering Corporation Engineered anti-IL-23R antibodies
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009002521A2 (en) 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009037190A2 (en) 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
EP2265644A4 (en) 2008-03-14 2011-04-27 Biocon Ltd MONOCLONAL ANTIBODY AND CORRESPONDING METHOD
US9403904B2 (en) 2008-11-07 2016-08-02 Fabrus, Inc. Anti-DLL4 antibodies and uses thereof
CA2781467C (en) 2009-11-20 2015-10-13 Biocon Limited Formulations of antibody
CN102559636B (zh) 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
CU24312B1 (es) 2013-07-23 2018-02-08 Biocon Ltd Métodos para controlar los niveles de fucosilación en proteínas
JP6530391B2 (ja) 2013-07-23 2019-06-12 バイオコン・リミテッド Ｃｄ６結合パートナーの使用およびそれに基づく方法
CN109311992B (zh) 2016-06-15 2022-10-18 克利夫兰临床基金会 用于治疗t细胞介导疾病的新型抗cd6抗体
WO2018073721A1 (en) 2016-10-18 2018-04-26 Biocon Limited Use of itolizumab to reduce phosphorylation of cd6
DK3529274T3 (da) 2016-10-21 2024-06-17 Biocon Ltd Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus
US11198851B2 (en) 2016-10-28 2021-12-14 Inserm (Institut National De La Sante Et De La Rechere Medicale) Ex vivo generation of γδ Foxp3+ regulatory T cells and therapeutic uses thereof
AU2019228508A1 (en) 2018-02-27 2020-09-17 Equillium, Inc. Anti CD6 antibodies for treating severe asthma
SG11202109118XA (en) 2019-02-26 2021-09-29 Equillium Inc Anti-cd6 antibody compositions and methods for treating lupus
US20230151107A1 (en) 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
WO2022120240A1 (en) 2020-12-04 2022-06-09 Equillium, Inc. Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells

Also Published As

Publication number Publication date
JP5856209B2 (ja) 2016-02-09
US9670285B2 (en) 2017-06-06
US20140031529A1 (en) 2014-01-30
US10669346B2 (en) 2020-06-02
ZA201005843B (en) 2011-04-28
US10000573B2 (en) 2018-06-19
TWI485160B (zh) 2015-05-21
EP2993186B1 (en) 2019-09-04
US20160168256A1 (en) 2016-06-16
US20180258179A1 (en) 2018-09-13
HK1223941A1 (zh) 2017-08-11
AU2008352540A1 (en) 2009-09-17
AU2008352540B2 (en) 2012-06-28
CA2716919A1 (en) 2009-09-17
CN101970493A (zh) 2011-02-09
US9217037B2 (en) 2015-12-22
UY31710A (es) 2009-11-10
EP2993186A1 (en) 2016-03-09
TW201000125A (en) 2010-01-01
NZ587632A (en) 2012-06-29
US11981743B2 (en) 2024-05-14
EA201001467A1 (ru) 2011-06-30
JP2011513479A (ja) 2011-04-28
US20170281808A1 (en) 2017-10-05
CO6331445A2 (es) 2011-10-20
WO2009113083A1 (en) 2009-09-17
ES2759075T3 (es) 2020-05-07
MY159517A (en) 2017-01-13
EP2265644A4 (en) 2011-04-27
JP2014065711A (ja) 2014-04-17
IL207917A0 (en) 2010-12-30
US20210122829A1 (en) 2021-04-29
AR072247A1 (es) 2010-08-18
BRPI0822447A2 (pt) 2015-06-16
KR20100126811A (ko) 2010-12-02
US20240417483A1 (en) 2024-12-19
MX2010010085A (es) 2011-03-29
EP2265644A1 (en) 2010-12-29
US20110002939A1 (en) 2011-01-06
CL2009000618A1 (es) 2011-05-27
UA104587C2 (ru) 2014-02-25
DK2993186T3 (da) 2019-11-25
US8524233B2 (en) 2013-09-03
JP2014159425A (ja) 2014-09-04
CA2716919C (en) 2015-01-20
PT2993186T (pt) 2019-11-29

Similar Documents

Publication Publication Date Title
HK1223941A1 (zh) 單克隆抗體及其方法
SG10201601279SA (en) Monoclonal Antibody STRO-4
EP2331579A4 (en) MONOCLONAL ANTIBODIES
IL201082A0 (en) Bispecific antibodies and methods for production thereof
EP2021373A4 (en) MONOCLONAL ANTIBODY VCAM-1 SPECIFIC
PT2374883T (pt) Anticorpo anti-cd4
HK1194395A1 (zh) 抗體及其製備和使用方法
ZA200809662B (en) Modified humanised anti-interleukin-18 antibodies
ZA201005348B (en) Humanized anti-c5ar antibodies
ZA201207484B (en) Humanized anti-egfl7 antibodies and methods using same
PT2510011E (pt) Anticorpos monoclonais que se ligam a b7h6 e suas utilizações
IL192419A0 (en) Anti-ephb4 antibodies and methods using same
IL204835A0 (en) Humanized antibody
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
IL231891A0 (en) Anti-2ephriinb antibodies and methods of using them
SI2094728T1 (sl) Postopki za uporabo za humano-adaptivnost monoklonskih protiteles
HK1158977A1 (zh) 抗膜鐵轉運蛋白 單克隆抗體及其用途
ZA200806053B (en) Anti-EphB4 antibodies and methods using same
GB0804684D0 (en) Humanized antibody
GB0804686D0 (en) Humanized antibody
GB0804687D0 (en) Humanized antibody
GB0706965D0 (en) Humanized antibody
GB0706963D0 (en) Humanized antibody
GB0706964D0 (en) Humanized antibody